ClinicalTrials.gg
CompletedNCT07913789Updated Nov 3, 2026

Opioid Free Anesthesia Combined With Pectoral Nerve Block (PECS Block) in Breast Cancer Surgery

An interventional study of Opioid Free Anesthesia and Opioid based anesthesia in Opioid Free Anesthesia, Pectoral Nerve Block and Breast Cancer Surgery, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2025, registered Oct 2026).
Updated Nov 3, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Breast Neoplasms by Tanta University — 4 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · Tanta University.

Enrollment
5th of 14
60 · median 48
Started
2025
with 2 others
No phase
2 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Breast Neoplasms by Tanta University, this one is the 5th largest by enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 14 studies in Breast Neoplasms by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Neoplasms by Tanta University, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy of opioid free anesthesia combined with pectoral Nerve Block (PECS block) in patients undergoing breast cancer surgery.

Read the detailed description

Breast cancer is the most commonly diagnosed neoplasm in women and accounts for nearly a third (29%) of all malignancies, representing the leading cause of cancer death among women worldwide.

Pectoralis Nerve Block (PECS), is an ultrasound-guided regional anesthesia technique used to block the nerves of the chest wall, providing analgesia for breast surgery and other anterior chest wall procedures.

03

Conditions studied

  • Opioid Free Anesthesia
  • Pectoral Nerve Block
  • Breast Cancer Surgery

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-65 years.
  • (ASA) physical status I-II.
  • Scheduled unilateral breast cancer surgery.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate in the study
  • Psychiatric disorder, communication difficulties and chronic neurological disease.
  • History of allergy to local anesthetics.
  • Patients with bleeding disorders, on anticoagulants or with skin infection at the site of injection.
  • Patients with pre-existing severe major organ dysfunction such as cardiac, hepatic, renal impairment.
  • (BMI) ≥ 35 kg/m2.
  • Chest wall deformity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Opioid Free Anesthesia Group

    Patients received ultrasound-guided pectoral nerve block (PECS) using 30 mL of 0.25% bupivacaine after induction of anesthesia. General Anesthesia was induced in an opioid-free manner.

    Procedure: Opioid Free Anesthesia

  • Active comparator
    Opioid based anesthesia Control Group

    Patients received conventional general anesthesia with intraoperative opioids as per institutional protocol.

    Procedure: Opioid based anesthesia

Interventions

  • ProcedureOpioid Free Anesthesia

    Patients received ultrasound-guided pectoral nerve block (PECS) using 30 mL of 0.25% bupivacaine after induction of anesthesia. General Anesthesia was induced in an opioid-free manner.

  • ProcedureOpioid based anesthesia

    Patients received conventional general anesthesia with intraoperative opioids as per institutional protocol.

06

What researchers measure

Primary outcomes

  1. Total morphine consumption

    For each patient with \[Visual Analogue Scale (VAS) \> 4\], 3 mg of morphine will be prescribed as rescue analgesia to be repeated after 30 min if pain persists until the VAS\< 4.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Heart rate

    Heart rate was recorded at baseline, after performing of block, and every 15 min till the end of surgery.

    Time frame: Till the end of surgery (Up to 2 hours)

  2. Mean arterial blood pressure

    Mean arterial blood pressure was recorded at baseline, after performing of block, and every 15 min till the end of surgery.

    Time frame: Till the end of surgery (Up to 2 hours)

  3. Degree of pain

    All the participants were explained about postoperative pain assessment with the visual analogue scale (VAS), from 0 to 10 (0 represents "no pain" while 10 represents "the worst pain imaginable")

    Time frame: 24 hours postoperatively

  4. Time to extubation

    The time to extubate was counted starting from stoppage of inhalational anesthetic agent till the extubating was practiced.

    Time frame: Till the extubating (Up to 60 minutes)

  5. Quality of recovery

    Quality of recovery was assessed using Modified Aldrete Score (depending on conscious level, activity of the patient, breathing, blood pressure, oxygen saturation).

    Time frame: 24 hours postoperatively

  6. Time to the 1st rescue analgesia

    Time to the first request for the rescue analgesia was recorded from end of surgery to first dose of morphine administrated.

    Time frame: 24 hours postoperatively

  7. Incidence of side effects

    Incidence of side effects such as bradycardia, hypotension, nausea, vomiting, respiratory depression, hematoma at the site of injection, and local anesthetic toxicity were recorded.

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Tanta University
    Tanta, El-Gharbia 31527, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Oct 2026, 12 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 12 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 3, 2026
StartActual
Oct 1, 2025
Primary completionActual
Oct 1, 2026
CompletionActual
Oct 1, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07913789
Lead sponsor
Tanta University
Responsible party
Ahmed Mohamed Eloraby Eloraby (Resident of Anesthesiology, Surgical Intensive Care and Pain Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Nov 3, 2026
Start date
Oct 1, 2025
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Nov 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion